Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Obesity 3Breast Neoplasms 3Prostatic Neoplasms 2Overweight 2Melanoma 2Substance Withdrawal Syndrome 1Skin Neoplasms 1Metabolic Syndrome 1Kidney Neoplasms 1Inflammation 1Glioma 1Glioblastoma 1Dyslipidemias 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Morphine 7Surveys and Questionnaires 6Ketamine 5Fentanyl 4Sodium Chloride 3Saline Solution 3Lidocaine 3Educational Status 3Dexmedetomidine 3Cognitive Behavioral Therapy 3Anesthetics, Local 3ziconotide 2Pregabalin 2Mindfulness-Based Stress Reduction 2Hypnosis 2Control Groups 2Bupivacaine 2Acetaminophen 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2tianeptine 1siltuximab 1onabotulinum toxin A 1nabiximols 1morphine, naltrexone combination 1erenumab 1Yoga 1Waiting Lists 1Transcutaneous Electric Nerve Stimulation 1Tramadol 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chronic Pain × Naltrexone × Clear all
NCT01100437 2012-07-13

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

Pfizer

Phase 4 Terminated
14 enrolled 18 charts

Substance Withdrawal Syndrome, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡